|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Prasad SM, Decastro GJ, Steinberg GD and
Medscape: Urothelial carcinoma of the bladder: Definition,
treatment and future efforts. Nat Rev Urol. 8:631–642. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chenivesse C and Tsicopoulos A:
CCL18-Beyond chemotaxis. Cytokine. 109:52–56. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang Q, Tang Y, Yu H, Yin Q, Li M, Shi L,
Zhang W, Li D and Li L: CCL18 from tumor-cells promotes epithelial
ovarian cancer metastasis via mTOR signaling pathway. Mol Carcinog.
55:1688–1699. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shi L, Zhang B, Sun X, Zhang X, Lv S, Li
H, Wang X, Zhao C, Zhang H, Xie X, et al: CC chemokine ligand
18(CCL18) promotes migration and invasion of lung cancer cells by
binding to Nir1 through Nir1-ELMO1/DOC180 signaling pathway. Mol
Carcinog. 55:2051–2062. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang H, Liang X, Li M, Tao X, Tai S, Fan
Z, Wang Z, Cheng B and Xia J: Chemokine (CC motif) ligand 18
upregulates Slug expression to promote stem-cell like features by
activating the mammalian target of rapamycin pathway in oral
squamous cell carcinoma. Cancer Sci. 108:1584–1593. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen J, Yao Y, Gong C, Yu F, Su S, Chen J,
Liu B, Deng H, Wang F, Lin L, et al: CCL18 from tumor-associated
macrophages promotes breast cancer metastasis via PITPNM3. Cancer
Cell. 19:541–555. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Urquidi V, Kim J, Chang M, Dai Y, Rosser
CJ and Goodison S: CCL18 in a multiplex urine-based assay for the
detection of bladder cancer. PLoS One. 7:e377972012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Miyake M, Ross S, Lawton A, Chang M, Dai
Y, Mengual L, Alcaraz A, Giacoia EG, Goodison S and Rosser CJ:
Investigation of CCL18 and A1AT as potential urinary biomarkers for
bladder cancer detection. BMC Urol. 13:422013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
D'Ambrosio D, Iellem A, Bonecchi R, Mazzeo
D, Sozzani S, Mantovani A and Sinigaglia F: Selective up-regulation
of chemokine receptors CCR4 and CCR8 upon activation of polarized
human type 2 Th cells. J Immunol. 161:5111–5115. 1998.PubMed/NCBI
|
|
12
|
Roos RS, Loetscher M, Legler DF,
Clark-Lewis I, Baggiolini M and Moser B: Identification of CCR8,
the receptor for the human CC chemokine I-309. J Biol Chem.
272:17251–17254. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Islam SA, Ling MF, Leung J, Shreffler WG
and Luster AD: Identification of human CCR8 as a CCL18 receptor. J
Exp Med. 210:1889–1898. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Riester M, Taylor JM, Feifer A, Koppie T,
Rosenberg JE, Downey RJ, Bochner BH and Michor F: Combination of a
novel gene expression signature with a clinical nomogram improves
the prediction of survival in high-risk bladder cancer. Clin Cancer
Res. 18:1323–1333. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Oshio T, Kawashima R, Kawamura YI,
Hagiwara T, Mizutani N, Okada T, Otsubo T, Inagaki-Ohara K,
Matsukawa A, Haga T, et al: Chemokine receptor CCR8 is required for
lipopolysaccharide-triggered cytokine production in mouse
peritoneal macrophages. PLoS One. 9:e944452014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Leung SY, Yuen ST, Chu KM, Mathy JA, Li R,
Chan AS, Law S, Wong J, Chen X and So S: Expression profiling
identifies chemokine (C-C motif) ligand 18 as an independent
prognostic indicator in gastric cancer. Gastroenterology.
127:457–469. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mittal V: Epithelial mesenchymal
transition in tumor metastasis. Annu Rev Pathol. 13:395–412. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fu B, Wang Y, Zhang X, Lang B, Zhou X, Xu
X, Zeng T, Liu W, Zhang X, Guo J and Wang G: miR-221-induced PUMA
silencing mediates immune evasion of bladder cancer cells. Int J
Oncol. 46:1169–1180. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Catusse J, Wollner S, Leick M, Schröttner
P, Schraufstätter I and Burger M: Attenuation of CXCR4 responses by
CCL18 in acute lymphocytic leukemia B cells. J Cell Physiol.
225:792–800. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
McConkey DJ, Choi W, Marquis L, Martin F,
Williams MB, Shah J, Svatek R, Das A, Adam L, Kamat A, et al: Role
of epithelial-to-mesenchymal transition (EMT) in drug sensitivity
and metastasis in bladder cancer. Cancer Metastasis Rev.
28:335–344. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Orlichenko LS and Radisky DC: Matrix
metalloproteinases stimulate epithelial-mesenchymal transition
during tumor development. Clin Exp Metastasis. 25:593–600. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Deryugina EI and Quigley JP: Matrix
metalloproteinases and tumor metastasis. Cancer Metastasis Rev.
25:9–34. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Davies B, Waxman J, Wasan H, Abel P,
Williams G, Krausz T, Neal D, Thomas D, Hanby A and Balkwill F:
Levels of matrix metalloproteases in bladder cancer correlate with
tumor grade and invasion. Cancer Res. 53:5365–5369. 1993.PubMed/NCBI
|
|
26
|
Kanayama HO, Yokota KY, Kurokawa Y,
Murakami Y, Nishitani M and Kagawa S: Prognostic values of matrix
metalloproteinase-2 and tissue inhibitor of metalloproteinase-2
expression in bladder cancer. Cancer. 82:1359–1366. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
He W, Zhong G, Jiang N, Wang B, Fan X,
Chen C, Chen X, Huang J and Lin T: Long noncoding RNA BLACAT2
promotes bladder cancer-associated lymphangiogenesis and lymphatic
metastasis. J Clin Invest. 128:861–875. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mandriota SJ, Jussila L, Jeltsch M,
Compagni A, Baetens D, Prevo R, Banerji S, Huarte J, Montesano R,
Jackson DG, et al: Vascular endothelial growth factor-C-mediated
lymphangiogenesis promotes tumour metastasis. EMBO J. 20:672–682.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Suzuki K, Morita T and Tokue A: Vascular
endothelial growth factor-C (VEGF-C) expression predicts lymph node
metastasis of transitional cell carcinoma of the bladder. Int J
Urol. 12:152–158. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Miyata Y, Kanda S, Ohba K, Nomata K,
Hayashida Y, Eguchi J, Hayashi T and Kanetake H: Lymphangiogenesis
and angiogenesis in bladder cancer: Prognostic implications and
regulation by vascular endothelial growth factors-A, -C, and -D.
Clin Cancer Res. 12:800–806. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen JC, Chang YW, Hong CC, Yu YH and Su
JL: The role of the VEGF-C/VEGFRs axis in tumor progression and
therapy. Int J Mol Sci. 14:88–107. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Keck B, Wach S, Taubert H, Zeiler S, Ott
OJ, Kunath F, Hartmann A, Bertz S, Weiss C, Hönscheid P, et al:
Neuropilin-2 and its ligand VEGF-C predict treatment response after
transurethral resection and radiochemotherapy in bladder cancer
patients. Int J Cancer. 136:443–451. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rinderknecht M, Villa A, Ballmer-Hofer K,
Neri D and Detmar M: Phage-derived fully human monoclonal antibody
fragments to human vascular endothelial growth factor-c block its
interaction with VEGF receptor-2 and 3. PLoS One. 5:e119412010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Eruslanov E, Stoffs T, Kim WJ, Daurkin I,
Gilbert SM, Su LM, Vieweg J, Daaka Y and Kusmartsev S: Expansion of
CCR8(+) inflammatory myeloid cells in cancer patients with
urothelial and renal carcinomas. Clin Cancer Res. 19:1670–1680.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li D, Duell EJ, Yu K, Risch HA, Olson SH,
Kooperberg C, Wolpin BM, Jiao L, Dong X, Wheeler B, et al: Pathway
analysis of genome-wide association study data highlights
pancreatic development genes as susceptibility factors for
pancreatic cancer. Carcinogenesis. 33:1384–1390. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Berenguer J, Lagerweij T, Zhao XW, Dusoswa
S, van der Stoop P, Westerman B, de Gooijer MC, Zoetemelk M, Zomer
A, Crommentuijn MHW, et al: Glycosylated extracellular vesicles
released by glioblastoma cells are decorated by CCL18 allowing for
cellular uptake via chemokine receptor CCR8. J Extracell Vesicles.
7:14466602018. View Article : Google Scholar : PubMed/NCBI
|
